ST. LOUIS, Dec. 13 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED), a Next Generation DM(TM) (Disease Management) company that uses genomics to improve clinical outcomes, announced today that it's nearly three-year old claim that angiotensin I-converting enzyme (ACE) is a major aging gene in humans was independently corroborated by a researcher working at the University of California at Irvine, Dr. Hamdi K. Hamdi.
GenoMed filed a patent application in February, 2002 claiming that inhibiting ACE was part of the "Fountain of Youth." This claim was based on its finding that most common diseases of aging were caused by a variant of the ACE gene which led to overactivity of the enzyme. Dr. David Moskowitz, GenoMed's CEO, published "Is ACE a 'Master' Disease Gene?" in October, 2002 in Diabetes Technology and Therapeutics.
Publishing in Biochemical and Biophysical Research Communications, Dr. Hamdi and colleagues showed in July, 2002 that the same variant of the ACE gene was associated with age-related macular degeneration, a major cause of blindness in the elderly. In October, 2003 and May, 2004, Dr. Hamdi and associates published two critical papers showing that ACE inhibition in endothelial cells (the cells that line the wall of blood vessels) induces prolonged survival and immortalization factors that protect the cells from dying. Dr. Moskowitz has published several papers on the molecular mechanism of action of the ACE enzyme.
Said Dr. David Moskowitz, GenoMed's CEO, "We are thrilled to have received completely independent corroboration of our central hypothesis that ACE is a major human aging gene. Dr. Hamdi's work in cell and molecular biology complements our work at the molecular and clinical levels. What's even more satisfying is that our intellectual property position is so strong. We are in an excellent legal and business position to improve global public health. This is a wonderful day for GenoMed, and a great day for everybody over the age of 40."
Said Dr. Hamdi of UC Irvine, "This is a revolutionary concept that will change our view of disease and longevity."
About GenoMed
GenoMed is leading the clinical revolution which knowledge of the major aging gene has already made possible. GenoMed is currently marketing its protocol for preventing kidney failure due to high blood pressure and diabetes, and delaying emphysema. The Company is collaborating on numerous additional clinical trials, including one for influenza, since inhibiting ACE may work as a broad-spectrum viral antidote. To enroll in one of GenoMed's free clinical trials, please email dwmoskowitz@genomed.com.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether it can be shown over the next few decades that inhibiting ACE will extend life, and (b) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
GenoMed, Inc.